Fulltext

Ameliorative effect of IDS30, a stinging nettle leaf extract, on chronic colitis

Konrad, Astrid ; Mähler, Michael ; Arni, Stephan ; Flogerzi, Beatrice ; Klingelhöfer, Sonja ; Seibold, Frank

In: International Journal of Colorectal Disease, 2005, vol. 20, no. 1, p. 9-17

Ajouter à la liste personnelle
    Titre
    • Ameliorative effect of IDS30, a stinging nettle leaf extract, on chronic colitis
    Auteur
    • Konrad, Astrid. Division of Gastroenterology, Inselspital, University Hospital, University of Bern, Freiburgstrasse, 3010, Berne, Switzerland
    • Mähler, Michael. Central Animal Facility and Institute for Laboratory Animal Science, Medical School Hannover, 30623, Hannover, Germany
    • Arni, Stephan. Division of Gastroenterology, Inselspital, University Hospital, University of Bern, Freiburgstrasse, 3010, Berne, Switzerland
    • Flogerzi, Beatrice. Division of Gastroenterology, Inselspital, University Hospital, University of Bern, Freiburgstrasse, 3010, Berne, Switzerland
    • Klingelhöfer, Sonja. Strathmann AG, Hamburg, Germany
    • Seibold, Frank. Division of Gastroenterology, Inselspital, University Hospital, University of Bern, Freiburgstrasse, 3010, Berne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • International Journal of Colorectal Disease, 2005, vol. 20, no. 1, p. 9-17. Springer-Verlag; http://www.springer.de
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:310188
    Summary
    Background and aims: Anti-TNF-α antibodies are very effective in the treatment of acute Crohn's disease, but are limited by the decline of their effectiveness after repeated applications. The stinging nettle leaf extract, IDS30, is an adjuvant remedy in rheumatic diseases dependent on a cytokine suppressive effect. We investigated the effect of IDS30 on disease activity of murine colitis in different models. Methods: C3H.IL-10−/− and BALB/c mice with colitis induced by dextran sodium sulphate (DSS) were treated with either IDS30 or water. Mice were monitored for clinical signs of colitis. Inflammation was scored histologically, and faecal IL-1β and mucosal cytokines were measured by ELISA. Mononuclear cell proliferation of spleen and Peyer's patches were quantified by 3H-thymidine. Results: Mice with chronic DSS colitis or IL-10−/− mice treated with IDS30 clinically and histologically revealed significantly (p<0.05) fewer signs of colitis than untreated animals. Furthermore, faecal IL-1β and mucosal TNF-α concentrations were significantly lower (p<0.05) in treated mice. Mononuclear cell proliferation after stimulation with lipopolysaccharide was significantly (p<0.001) reduced in mice treated with IDS30. Conclusions: The long-term use of IDS30 is effective in the prevention of chronic murine colitis. This effect seems to be due to a decrease in the Th1 response and may be a new therapeutic option for prolonging remission in inflammatory bowel disease